Get started
Author

Christine L. Talarico

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
2020 · Susan Swindells, Jaime-Federico Andrade-Villanueva, et al. · New England Journal of Medicine · 641
PDF
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
1992 · V. Sullivan, C. L. Talarico, et al. · Nature · 473
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
2020 · Edgar T Overton, Gary Richmond, et al. · The Lancet · 400
Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of Action
2002 · Karen K. Biron, Robert J. Harvey, et al. · Antimicrobial Agents and Chemotherapy · 373
Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance
1995 · S. Chou, A. Erice, et al. · The Journal of Infectious Diseases · 240
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
2021 · Amy G. Cutrell, Jonathan M. Schapiro, et al. · AIDS · 226
A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives
1993 · V Sullivan, K K Biron, et al. · Antimicrobial Agents and Chemotherapy · 173
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
2020 · Giuliano Rizzardini, Edgar T. Overton, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 172
Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding
2002 · Jacob P. Lalezari, Judith A. Aberg, et al. · Antimicrobial Agents and Chemotherapy · 151
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
2021 · Hans Jaeger, Edgar T Overton, et al. · The Lancet HIV · 150
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
2019 · Kelly E Dooley, Richard Kaplan, et al. · Clinical Infectious Diseases · 123
PDF
Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS
1993 · C L Talarico, W C Phelps, et al. · Journal of Virology · 113
PDF
Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS
1994 · G. Boivin, C. K. Edelman, et al. · The Journal of Infectious Diseases · 111
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate
1995 · F Baldanti, E Silini, et al. · Journal of Virology · 110
Acyclovir Is Phosphorylated by the Human Cytomegalovirus UL97 Protein
1999 · Christine L. Talarico, Thimysta C. Burnette, et al. · Antimicrobial Agents and Chemotherapy · 105
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
2021 · Susan Swindells, Thomas Lutz, et al. · AIDS · 99
Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir
1995 · M N Hanson, L C Preheim, et al. · Antimicrobial Agents and Chemotherapy · 94
Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
1999 · E M Westphal, A Mauser, et al. · PubMed · 74
The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients
1998 · Fausto Baldanti, Mark R. Underwood, et al. · Antimicrobial Agents and Chemotherapy · 70
PDF
GSK983: A novel compound with broad-spectrum antiviral activity
2009 · Robert Harvey, Kevin Brown, et al. · Antiviral Research · 69
PDF
Characterization of an Acyclovir‐Resistant Herpes Simplex Virus Type 2 Strain Isolated from a Premature Neonate
2000 · Ronda J. Oram, Daniel Marcellino, et al. · The Journal of Infectious Diseases · 55
Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole l -Riboside 1263W94
2001 · James J. McSharry, Ann McDonough, et al. · Clinical and Diagnostic Laboratory Immunology · 53
Erratum: A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
1992 · V. Sullivan, C. L. Talarico, et al. · Nature · 46
PDF
Partial Substitution of the Functions of the Herpes Simplex Virus 1 UL13 Gene by the Human Cytomegalovirus UL97 Gene
1996 · Teresa I. Ng, Christine Talarico, et al. · Virology · 44
PDF
Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance
2001 · Henry H. Balfour, Charlene K. Edelman, et al. · The Pediatric Infectious Disease Journal · 42
Works count: 39
Citation count: 4,492
H-index: 29
I10-index: 31
Year
Topic
Type